New Cross-Regimen Analysis of HEALEY ALS Platform Trial Shows Significant Survival AdvantageSALT LAKE CITY, March 12, 2025 (GLOBE NEWSWIRE) -- Clene, Inc. (Nasdaq: CLNN) and its subsidiary, Clene ...

AKGsOVIHAMS, a leading healthcare institution, has marked progress in treating ALS using integrative medicine. Known for combining conventional and alternative therapies, the institute has shown ...

Noon, is tackling ALS and other neurological disorders with a bold, multi-targeted approach. Fueled by a personal encounter ...

A Regina mother who was one of the first ALS patients to test a new treatment is now celebrating its accelerated approval in Canada for adults with an ultra-rare form of the disease.

Columnist Dagmar Munn says she has often felt out of place in the ALS community because of the slower pace of her disease ...

Tiziana is seeking FDA clearance for a Phase 2 clinical trial testing the safety and efficacy of its foralumab nasal spray in ...

Clene (CLNN) and its subsidiary, Clene Nanomedicine announced new evidence from a cross-regimen, post hoc analysis of long-term survival in ...

Denali Therapeutics’ amyotrophic lateral sclerosis (ALS) drug has racked up another clinical miss this year, leaving the ...

ALS, which is also known as Lou Gehrig's Disease, is a rare neurological disease that affects motor neurons — the nerve cells ...

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of eleven abstracts covering research in amyotrophic lateral sclerosis (ALS) at the 2025 Muscular Dystrophy Association ...